This study identifies valerate as a biased ligand for GABA<sub>B</sub> receptor, which specifically binds the GABBR1 subunit, upregulates its expression, and thereby mediates CD8<sup>+</sup> T cell anti-tumor immunity in NSCLC. Here, CD8A is linked to neoplasm.